A new policy issued by the Centers for Medicare and Medicaid Services (CMS) limiting reimbursement for fluorescence in situ hybridization (FISH) testing to just one procedure regardless of how many probes are used would result in underpayment to clinical and anatomic pathology laboratories, says the American Clinical Laboratory Association (ACLA) in a letter to CMS…

This content is for Paid Members only.
Login Register